Corvus Pharmaceuticals CRVS Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -32.6%+142pp | -174.9%-118pp | -57%-3.1pp | -53.9%-2.8pp | |
| Return on invested capital | -104.2%+1.0pp | -105.2%-41.0pp | -64.1%+14.4pp | -78.6%+2.5pp | |
| Liquidity | |||||
| Current ratio | 6.2×+4.7× | 1.5×-2.5× | 4.1×0.0× | 4.1×-3.3× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $0.77+43.7% | $0.53-33.7% | $0.81-33.2% | $1.21-48.1% | |
| Valuation | |||||
| Market capitalization | $1.1B+259% | $343.78M+298% | $86.31M+118% | $39.57M-64.7% | |
| Price / book | 4.6×-1.6× | 10.6×+8.3× | 2.2×+1.5× | 0.7×-0.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Corvus Pharmaceuticals's ratios come from?
- Every ratio is computed from Corvus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.